Glioblastoma Multiforme is the most common malignant tumor of the central nervous system. It is resistant to current methods of treatment and is associated with a poor prognosis. The elucidation of novel strategies to kill glial tumor cells is thus an urgent need. The epidermal growth factor receptor (EGFR) gene is amplified and over- expressed in about half of these tumors. Epidermal growth factor acts as a mitogen and over-expression of its receptor may contribute to the excessive proliferation seen in cancer. However, ligand stimulation of cells over-expressing the EGFR also has been shown to induce apoptosis. Thus a key answered question in tumor biology is: what are the factors which determine whether excessive activation of growth factor receptors leads to mitogenesis versus apoptosis? An improved understanding of mechanisms involved in the preferential activation of apoptosis may lead to more effective treatment. Our first approach will e to use inducible transfection systems to determine the threshold of receptor expression in glioma cells whereby a mitogenic signal changes to a death signal. Our preliminary data suggests that over-expression of the EGFR results in the aberrant activation of cell death pathways and leads to the recruitment of key proteins involved in apoptosis such as RIP and Caspase-8 to the EGFR mediated apoptosis in glioma cells in vitro as well as in animal models of glial tumors. The applicant is a board-certified neurologist who has taken care of patients with nervous system tumors and is committed to a career in academic neuro-oncology. The program outlined in this application provides a rigorous and intensive didactic and research experience, which will enable the applicant to pursue a career as an independent researcher. The mentor is the Director of Cancer Biology at Beth Israel Deaconess Medical Center (BIDMC), and has extensive experience in signal transduction mediated by receptor tyrosine kinases. The clinical mentor is a neuro-oncologist who is the Co-Director of the Brain Tumor Center at BIDMC. The academic environment at Harvard Medical School at BIDMC is well suited to pursue the goals outlined in this application.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lohrey, Nancy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Park, Seongmi; Ramnarain, Deepti B; Hatanpaa, Kimmo J et al. (2008) The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway. EMBO Rep 9:766-73
Ramnarain, D B; Paulmurugan, R; Park, S et al. (2008) RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ 15:344-53
Nie, DU-Yu; Ma, Quan-Hong; Law, Janice W S et al. (2006) Oligodendrocytes regulate formation of nodes of Ranvier via the recognition molecule OMgp. Neuron Glia Biol 2:151-164
Ramnarain, Deepti B; Park, Seongmi; Lee, Diana Y et al. (2006) Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66:867-74
Habib, Amyn A; Chun, Soo Jin; Neel, Benjamin G et al. (2003) Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways. Mol Cancer Res 1:219-33
Hognason, T; Chatterjee, S; Vartanian, T et al. (2001) Epidermal growth factor receptor induced apoptosis: potentiation by inhibition of Ras signaling. FEBS Lett 491:9-15
Habib, A A; Chatterjee, S; Park, S K et al. (2001) The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276:8865-74